Dr. Erica Schwartz, President Trump’s nominee to lead the Centers for Disease Control and Prevention, has disclosed in a federal ethics filing that she would receive a substantial financial package from her current employer, UnitedHealth Group, before assuming the role of CDC director if confirmed by the Senate.
The filing, dated June 16 and released by the government on June 22, outlines the terms under which Schwartz would separate from the insurance company and transition to a government leadership position that oversees the nation’s primary public health agency. Schwartz committed in the filing to resigning from UnitedHealth upon confirmation, selling stock holdings that could present conflicts, and recusing herself from any matters involving her former employer for a defined period.
What the financial package includes
The terms of Schwartz’s departure from UnitedHealth are detailed in the ethics disclosure. Upon her termination from the company, she would receive a payment equivalent to one year’s salary as well as a bonus payment. She would also receive accelerated vesting of restricted stock units and stock options that would otherwise have continued to vest through August 2027 had she remained employed. Any stock grants or options that extend beyond that window would be forfeited when her employment ends.
The arrangement effectively converts future equity compensation into immediate cash payments at the moment of her departure for government service. That structure is not unusual for senior executives leaving the private sector for government positions, but it produces a significant financial event tied directly to the timing of her government appointment, a relationship that ethics reviewers and senators are expected to scrutinize during the confirmation process.
A two-year recusal commitment
Schwartz also committed to a two-year recusal period from any government matters involving UnitedHealth Group, calculated from the date of her last payment from the company. The recusal would prohibit her from participating in CDC decisions, regulatory actions, or policy matters where UnitedHealth has a direct interest, unless she receives a formal written waiver permitting her involvement.
UnitedHealth Group is one of the largest health insurance and managed care companies in the United States, with extensive interactions with federal health agencies including the CDC, the Centers for Medicare and Medicaid Services, and the Department of Health and Human Services. The scope of those interactions means the recusal commitment could be practically significant depending on how broadly it is interpreted and enforced.
The broader confirmation context
Schwartz is the latest nominee Trump has put forward for the CDC director position, a role that has carried heightened visibility and public scrutiny since the agency’s profile was dramatically elevated during the pandemic years. The CDC director oversees a sprawling agency responsible for disease surveillance, public health preparedness, vaccination programs, and emergency response coordination.
The ethics disclosure is a standard requirement for nominees to senior federal positions and is intended to provide senators and the public with a clear picture of the financial interests and potential conflicts a nominee would bring to the role. In Schwartz’s case the disclosure highlights the transition from a senior position at one of the country’s largest health insurers directly into leadership of a government agency that both regulates and interacts extensively with the private insurance sector.
The Senate has not yet scheduled confirmation hearings. When they occur, the UnitedHealth compensation arrangement is likely to be a central subject of inquiry from members of both parties who have been examining the relationship between the health insurance industry and federal health policy.
